Results SCFβ-TrCP1 Inhibited TGF-β Function in Pancreatic Cancer Cells because of Decreasing Smad4 Stability Previously, we found that an E3 ligase complex SCF β-TrCP1 is responsible for Smad4 degradation. F-box protein β-TrCP1 in this complex associates with Smad4 both in yeast and in mammalian cells, and SCF β-TrCP1-overexpressing cells display increased ubiquitination and degradation of Smad4. 46 To further determine the biological role of SCF β-TrCP1 in controlling Smad4 protein stability in pancreatic cancer cells, we examined the interaction of endogenous Smad4 with β-TrCP1 in PANC-1 cells using immunoprecipitation assays. Figure 1A shows that endogenous Smad4 in PANC-1 cells co-immunoprecipitated with β-TrCP1 by using antibody specific against β-TrCP1 (lane 2), but not co-immunoprecipitated with Skp2 (lane 3), another well-characterized F-box protein of SCF E3 ligase. Fbw subfamily consists of many F-box proteins besides β-TrCP1. 23,24 To investigate whether the interaction of β-TrCP1 and Smad4 is specific, we detected the association of other F-box proteins with Smad4. Unlike β-TrCP1 ( Figure 1B, lane 2; Figure 1C, lane 2), ectopically expressed Flag-β-TrCP2 ( Figure 1B, lane 3), Flag-Fbw2 ( Figure 1B, lane 4), HA-Fbw3 ( Figure 1C, lane 3), or HA-Fbw-5 ( Figure 1C, lane 4) has either undetectable or very weak interaction with Smad4. This indicates that β-TrCP1 is the specific F-box protein that recognizes Smad4. | Figure 1Specific interaction of Smad4 with β-TrCP1 in pancreatic cancer cells. A: Cell lysates of PANC-1 cells were immunoprecipitated using preimmune (lane 1), anti-β-TrCP1 (lane 2), or anti-Skp2 (lane 3) antibody, and the immunocomplex was detected (more ...) |
To determine whether SCF β-TrCP1-induced Smad4 degradation affects TGF-β-mediated transcriptional activity, we co-transfected a TGF-β-responsive luciferase reporter (SBE), 4-luc (four repeats of Smad-binding element) with SCF components (Cul1, Roc1, and β-TrCP1) in PANC-1 cells. TGF-β induces approximately threefold of luciferase activity, and SCF complex down-regulates the transcription activity (Figure 2A). To clarify the effect of SCF β-TrCP1 on TGF-β biological functional activity in pancreatic cancer cells, cell proliferation was investigated. SCF components, Cul1, Roc1, β-TrCP1, were transfected in PANC-1 cells with or without TGF-β1 treatment. TGF-β1 inhibited cell proliferation, and SCF restored such TGF-β1-induced cell proliferation (Figure 2B). The distribution of the cell population in the G 1 and S phases of the cell cycle was analyzed by flow cytometry after expression of SCF β-TrCP1 in PANC-1 cells. As shown in Figure 2C, left, cell growth was arrested by TGF-β treatment, as judged by the decreased number of cells in S phase and the concomitant increase of cells in the G 1 phase. SCF inhibited the TGF-β-induced cell growth arrest. Smad4 protein levels were significantly reduced in these SCF component transfected cells ( Figure 2C, right), suggesting that SCF β-TrCP1 inhibits TGF-β biological activity by decreasing Smad4 protein level. | Figure 2SCFβ-TrCP1 inhibited TGF-β function in pancreatic cancer cells due to decreasing Smad4 stability. A: SCFβ-TrCP1 inhibits TGF-β-induced gene transactivation in pancreatic cancer cells. SBE-lux luciferase reporters were co-transfected (more ...) |
Low Smad4 Protein Level in Human Pancreatic Ductal Adenocarcinoma To investigate whether Smad4 protein instability is a common phenomenon in human pancreatic tumor cells, immunohistochemistry was conducted in 35 cases of pancreatic ductal adenocarcinoma. In all sections, chronic pancreatitic ductal cells could be seen adjacent to carcinoma cells. The percentage of cells positive of Smad4 protein staining was evaluated. Only those cases with greater than 10% immunohistochemical stains were considered as positive. The case distribution positive of Smad4 protein expression in the 35 sections with either chronic pancreatitis or pancreatic adenocarcinoma is demonstrated in Table 1. Of 35 patients, 30 (85.7%) were evaluated as Smad4-negative and the rest 5 (14.3%) were positive in carcinoma cells. In contrast, 31 (88.6%) were evaluated as Smad4-positive and the rest 4 (11.4%) were negative in adjacent chronic pancreatitic ductal cells. Cytoplasmic and occasional nuclear immunoreactivity was noted in all of the cases with positive staining of Smad4 (Figure 3). Smad4 was strongly expressed in relative normal or chronic pancreatitic ductal cells (Figure 3C), however, Smad4 was either undetectable or very weak in most of the pancreatic ductal adenocarcinomas (Figure 3D). | Table 1 The Distribution of Smad4 Protein Expression in Pancreatic Carcinoma and Chronic Pancreatitis Ductal Cells from 35 Pancreatic Adenocarcinoma Patients |
| Figure 3Immunohistochemistry of human pancreatic adenocarcinoma sections. A: H&E staining of a section from pancreatic tissue adjacent to pancreatic ductal carcinoma demonstrates lack of acinar cells, increased fibrosis, and proliferation of reactive (more ...) |
Pancreatic Tumor-Derived Point Mutations of Smad4 Cause Protein Instability through Ubiquitin-Proteasome Pathway It has been demonstrated that some mutations in Smad4 have been shown to target the proteins for rapid degradation via the ubiquitin-proteasome pathway, 17–19 indicating that protein instability of Smad4 may contribute to its protein loss in pancreatic cancers. To investigate this possibility, seven Flag-tagged Smad4 expression constructs harboring Smad4 mutations previously identified from pancreatic tumor were generated (Table 2). These mutated (MT) and wild-type (WT) Flag-tagged Smad4 expression plasmids were transfected individually into 293T cells and cycloheximide was added after transfection. Both point mutations (m100 and m130) that lie on MH1 domain cause much quicker Smad4 protein degradation than the WT ( Figure 4A, top). The degradation rate of the three mutants (m351, m355, and m493), whose mutations reside on MH2 domain, also exhibit much quicker degradation than the WT ( Figure 4A, middle). The results indicate that rapid protein degradation is the main contributor leading to protein loss of most Smad4-harboring point mutations. However, the degradation rate of Smad4 m370 and m383, whose mutations are also within MH2 domain, has no obvious differences compared with the WT ( Figure 4A, bottom), which imply that rapid protein degradation may not be the primary defect for these two mutations. | Table 2 Seven Pancreatic Tumor-Derived Smad4 Point Mutations |
| Figure 4Pancreatic tumor-derived point mutations of Smad4 cause protein instability through ubiquitin-proteasome pathway. A: Protein degradation rate of point-mutated Smad4 increased compared with WT Smad4. 293T cells were co-transfected with Flag-tagged Smad4 (more ...) |
We next determined whether rapid protein degradation of human pancreatic tumor-derived Smad4 mutations is via the proteasome pathway. MG-132, a proteasome inhibitor, 50 was added to the cells. MG-132 significantly elevated the level of Smad4 protein in most point-mutated Smad4-transfected cells, including m100, m130, m351, m355, and m493 (Figure 4B), but not in m370, m383, and WT Smad4 transfected cells, indicating that the changes of Smad4 protein steady-state levels in most point-mutated Smad4-transfected cells were due to protein degradation via the 26S proteasome. We also examined whether the enhanced turnover observed in Smad4 mutants is mediated through ubiquitination. Individual MT or WT Smad4 expression plasmids were co-transfected with or without ubiquitin expression plasmid in 293T cells. As shown in Figure 4C, WT Smad4 exhibits very little ubiquitination with or without ubiquitin. Stronger ladders of high molecular weight, ubiquitin-conjugated Smad4 products were observed in most of the MT Smad4-transfected cells. Consistent with this, ubiquitination of Smad4 m370 and m383, although much higher than WT Smad4, has no comparable difference between with or without ubiquitin addition. Taken together, these results suggest that most of Smad4-harboring tumor-derived point mutations, except m370 and m383, are degraded more rapidly through ubiquitin-proteasome pathway when compared to their WT counterparts. Instability of Point-Mutated Smad4 Proteins Mediated by SCFβ-TrCP1 The low protein stability of point-mutated Smad4 raises the question of whether point-mutated Smad4 proteins interact with β-TrCP1. The interactions of mutated Smad4 with β-TrCP1 were detected by immunoprecipitation assays with Flag-tagged WT or MT Smad4 individually transfected 293T cells. The results indicated that β-TrCP1 interacted with WT and almost all of the Smad4 mutants (Figure 5A). Because the expression level of Smad4 in WT and MT are quite different, the density of the immunoprecipitated bands was quantitated. The interaction affinity of β-TrCP1 with most of Smad4 mutants, except m370 ( Figure 5B, lane 7), was much enhanced in comparison with the WT Smad4 (lane 2). These results indicate that the interaction of β-TrCP1 with these Smad4 mutants was enhanced. Consistent with the above observation, ubiquitination of most of the MT Smad4, except m370, by the SCF complex is stronger than the WT Smad4 in in vivo ubiquitination assays (Figure 5C), suggesting that tumor-derived Smad4 mutants exhibit a stronger interaction with its F-box protein β-TrCP1, thereby leading to their rapid degradation. | Figure 5Instability of point-mutated Smad4 proteins mediated by SCFβ-TrCP1. A: Interaction of point-mutated Smad4 proteins with β-TrCP1. 293T cells were transfected with the indicated plasmids. Immunoprecipitation assays were performed using anti-β-TrCP1 (more ...) |
Since we demonstrated that the use of RNAi was successfully inhibiting the expression of β-TrCP1 and enhancing the expression of endogenous Smad4, 46 we asked whether this RNAi functioned to increase the stability of tumor-derived Smad4 mutants. siβ-TrCP1 decreased the expression of β-TrCP1 ( Figure 5D, middle), and the expression of most of the Smad4 mutants is elevated ( Figure 5D, top). We did not demonstrate obvious enhancement of Smad4 expression level in lanes 10 (m370) and 12 (m383), which is consistent with the above results and indicate that the protein stability of Smad4 m370 and m383 is relatively high and may not degrade through SCF β-TrCP1 pathway. These results suggest that β-TrCP1 is a key factor in mediating the instability of most tumor-derived Smad4 mutants. SCFβ-TrCP1 Controls Smad4 Protein Stability in Cancer Cell Line Harboring Smad4 Point Mutation We then examined whether SCF β-TrCP1 is required for endogenous Smad4 protein rapid degradation in pancreatic cancer cells harboring Smad4 point mutation. PANC-1 cells has WT Smad4, whereas, AsPC-1 (m100) and Caco-2 (m351) cells harbor Smad4 point mutation. 12,51 Figure 6A shows that PANC-1 expresses high level of Smad4 protein ( Figure 6A, left and right panels, lane 1), and both AsPC-1 ( Figure 6A, left, lane 2), and Caco-2 ( Figure 6A, right, lane 2) expresses very low level of Smad4 protein. To clarify whether the low Smad4 protein expression in pancreatic cancer cell lines harboring Smad4 point mutation was the result of low Smad4 mRNA level, we evaluated the mRNA expression of Smad4 in cells by real-time reverse transcriptase-PCR. No significant differences in Smad4 mRNA expression were noted among PANC-1, AsPC-1, and Caco-2 cells (Figure 6B). A Smad4-deficient cell line, BxPC-3, exhibits no Smad4 mRNA expression as a negative control. | Figure 6Instability of endogenous Smad4 protein in pancreatic cancer cells harboring Smad4 point mutation. A: Smad4 protein expression in different human pancreatic cancer cell lines. Western blotting of cell lysates from PANC-1, AsPC-1, and Caco-2 cells with (more ...) |
Smad4 protein degradation rate was then determined in pancreatic cancer cell lines. Cycloheximide was added to PANC-1, AsPC-1, and Caco-2 cultures to prevent further Smad protein synthesis. The level of endogenous Smad4 m100 rapidly decreased after the addition of cycloheximide and almost disappeared at 8 hours ( Figure 6C, middle). In contrast, WT Smad4 was considerably more stable and was still present 16 hours after cycloheximide addition ( Figure 6C, top). The level of Smad4 m351 has a relatively lower degradation rate, however, degrades faster in comparison with the WT ( Figure 6C, bottom versus top). We next determined whether rapid protein degradation of this mutated Smad4 protein is via the proteasome pathway. MG-132 was added in PANC-1, AsPC-1, and Caco-2 cells. Consistent with Figure 6A, the expression level of Smad4 in AsPC-1 and Caco-2 was much lower than that in PANC-1 ( Figure 6D, left and right sides, lane 1 versus lane 3). MG-132 increased the level of Smad4 protein in both AsPC-1 ( Figure 6D, left and right sides, lane 2 versus lane 1). These results suggested that endogenous Smad4 m100 and m351 degrades rapidly in AsPC-1 and Caco-2 cells via proteasome pathway. To determine whether SCF β-TrCP1 is the key determinant for Smad4 protein rapid degradation in AsPC-1 and Caco-2 cells, we examined the interaction of endogenous Smad4 with β-TrCP1 in PANC-1, AsPC-1, and Caco-2 cells. Interaction was observed in all three cell lines. The middle panel in both sides of Figure 7A shows that the expression level of Smad4 in PANC-1 cells is much higher than that in AsPC-1 and Caco-2 cells, whereas the interaction of Smad4 with β-TrCP1 in AsPC-1 ( Figure 7A, left side, top) and Caco-2 ( Figure 7A, right side, top) cells is stronger than that in PANC-1 cells. | Figure 7SCFβ-TrCP1 controls Smad4 protein stability in pancreatic cancer cell line harboring Smad4 point mutation. A: Interaction of endogenous Smad4 with β-TrCP1 in pancreatic cancer cell lines. Cell lysates of PANC-1, ASPC-1, and Caco-2 cells (more ...) |
We attempted to investigate whether β-TrCP1 siRNA could elevate Smad4 level in pancreatic cancer cells. Because the efficiency of transient transfection of siRNA into pancreatic cancer cells is very low, we generated retrovirus constructs that contain ΔU/U6 empty vector, ΔU/U6/GFP (siGFP) and ΔU/U6/β-TrCP (siβ-TrCP1). High infection efficiencies of the siRNA in PANC-1, AsPC-1, and Caco-2 cells were yielded (data not shown). Consistent with the results in 293T cells, β-TrCP1 siRNA efficiently reduced the expression of β-TrCP1 ( Figure 7B, top), and the expression of Smad4 is elevated in all of the three cell lines ( Figure 7B, middle). We then examined whether β-TrCP1 silencing affects Smad4-mediated transcriptional activity in pancreatic cancer cells. TGF-β response reporter plasmids, (SBE)4-luc 52 and p15P114luc 53 were transfected in PANC-1, AsPC-1, and Caco-2 cells infected by retrovirus containing GFP siRNA or β-TrCP1 siRNA. TGF-β significantly stimulates luciferase activity in PANC-1 cells (Figure 8A) and has a mild effect in AsPC-1 (Figure 8B) and Caco-2 (Figure 8C). β-TrCP1 siRNA significantly increased TGF-β-induced transcriptional activity in both PANC-1 cells ( Figure 8A, P < 0.05) and Caco-2 cells ( Figure 8C, P < 0.05). However, the elevation of TGF-β-induced transcriptional activity mediated by β-TrCP1 siRNA has no statistical significance in AsPC-1 cells, indicating that Smad4 m100 has some functional defect in transducing TGF-β activity. To determine whether the function of β-TrCP1 siRNA on TGF-β response is through elevating Smad4 amount and DNA binding, two additional luciferase reporters containing Smad-binding site mutations, MBE6-lux 52 and p15SBE mutant-luc, 53 were transfected in PANC-1, AsPC-1, and Caco-2 cells infected by retrovirus containing GFP siRNA or β-TrCP1 siRNA. β-TrCP1 siRNA no longer increased TGF-β-induced transcriptional activity in these cells (Figure 8; A to C). Taken together, the results indicated that β-TrCP1 is a key molecule mediating Smad4 degradation and TGF-β functional loss in pancreatic cancer cells. | Figure 8Suppression of β-TrCP1 by retroviral delivery of siRNA into pancreatic cancer cells elevated TGF-β-mediated gene transcription. SBE-luc, MBE-luc, p15P114-luc, and p15Smad mutation-luc luciferase reporters were transfected into PANC-1 ( (more ...) |
|
References - Farrow, B; Evers, BM. Inflammation and the development of pancreatic cancer. Surg Oncol Oxf. 2002;10:153–169.
- Devesa, SS; Blot, WJ; Stone, BJ; Miller, BA; Tarone, RE; Fraumeni, JF., Jr Recent cancer trends in the United States. J Natl Cancer Inst. 1995;87:175–182. [PubMed]
- Korc, M. Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am. 1998;7:25–41. [PubMed]
- Ozawa, F; Friess, H; Tempia-Caliera, A; Kleeff, J; Buchler, MW. Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen. 2001;21:27–44. [PubMed]
- Hruban, RH; van Mansfeld, AD; Offerhaus, GJ; van Weering, DH; Allison, DC; Goodman, SN; Kensler, TW; Bose, KK; Cameron, JL; Bos, JL. K-ras oncogene activation in adenocarcinoma of the human pancreas: a study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 1993;143:545–554. [PubMed]
- Barton, CM; Staddon, SL; Hughes, CM; Hall, PA; O’Sullivan, C; Kloppel, G; Theis, B; Russell, RC; Neoptolemos, J; Williamson, RC; Lane, DP. Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer. Br J Cancer. 1991;64:1076–1082. [PubMed]
- Caldas, C; Hahn, SA; da Costa, LT; Redston, MS; Schutte, M; Seymour, AB; Weinstein, CL; Hruban, RH; Yeo, CJ; Kern, SE. Frequent somatic mutations and homozygous deletions of the p16 gene in pancreatic adenocarcinoma. Nat Genet. 1994;8:27–32. [PubMed]
- Yue, J; Mulder, KM. Transforming growth factor-β signal transduction in epithelial cells. Pharmacol Ther. 2001;91:1–34. [PubMed]
- Massague, J; Blain, SW; Lo, RS. TGF-β signaling in growth control, cancer, and heritable disorders. Cell. 2000;103:295–309. [PubMed]
- Massague, J. TGF-β signal transduction. Annu Rev Biochem. 1998;67:753–791. [PubMed]
- Hahn, SA; Schutte, M; Hoque, AT; Moskaluk, CA; da Costa, LT; Rozenblum, E; Weinstein, CL; Fischer, A; Yeo, CJ; Hruban, RH. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350–353. [PubMed]
- Schutte, M; Hruban, RH; Hedrick, L; Cho, KR; Nadasdy, GM; Weinstein, CL; Bova, GS; Isaacs, WB; Cairns, P; Nawroz, H. DPC4 gene in various tumor types. Cancer Res. 1996;56:2527–2530. [PubMed]
- Sunamura, M; Yatsuoka, T; Motoi, F; Duda, DG; Kimura, M; Abe, T; Yokoyama, T; Inoue, H; Oonuma, M; Takeda, K; Matsuno, S. Gene therapy for pancreatic cancer based on genetic characterization of the disease. J Hepatobiliary Pancreat Surg. 2002;9:32–38. [PubMed]
- Tascilar, M; Skinner, HG; Rosty, C; Sohn, T; Wilentz, RE; Offerhaus, GJ; Adsay, V; Abrams, RA; Cameron, JL; Kern, SE; Yeo, CJ; Hruban, RH; Goggins, M. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2001;7:4115–4121. [PubMed]
- Eppert, K; Scherer, SW; Ozcelik, H; Pirone, R; Hoodless, P; Kim, H; Tsui, LC; Bapat, B; Gallinger, S; Andrulis, IL. MADR2 maps to 18q21 and encodes a TGF-β-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 1996;86:543–552. [PubMed]
- Shi, Y; Hata, A; Lo, RS; Massague, J; Pavletich, NP. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature. 1997;388:87–93. [PubMed]
- Xu, J; Attisano, L. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 2000;97:4820–4825. [PubMed]
- Maurice, D; Pierreux, CE; Howell, M; Wilentz, RE; Owen, MJ; Hill, CS. Loss of Smad4 function in pancreatic tumors: c-terminal truncation leads to decreased stability. J Biol Chem. 2001;276:43175–43181. [PubMed]
- Moren, A; Hellman, U; Inada, Y; Imamura, T; Heldinn, CH; Moustakas, A. Differential ubiquitination defines the functional status of the tumor suppressor Smad4. J Biol Chem. 2003;278:33571–33582. [PubMed]
- DeSalle, LM; Pagano, M. Regulation of the G1 to S transition by the ubiquitin pathway. FEBS Lett. 2001;490:179–189. [PubMed]
- Pickart, CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001;70:503–533. [PubMed]
- Deshaies, RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol. 1999;15:435–467. [PubMed]
- Winston, JT; Koepp, DM; Zhu, C; Elledge, SJ; Harper, JW. A family of mammalian F-box proteins. Curr Biol. 1999;9:1180–1182. [PubMed]
- Cardozo, T; Pagano, M. The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol. 2004;5:739–751. [PubMed]
- Yaron, A; Hatzubai, A; Davis, M; Lavon, I; Amit, S; Manning, AM; Andersen, JS; Mann, M; Mercurio, F; Ben Neriah, Y. Identification of the receptor component of the IκBα-ubiquitin ligase. Nature. 1998;396:590–594. [PubMed]
- Fuchs, SY; Chen, A; Xiong, Y; Pan, ZQ; Ronai, Z. HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IκB and beta-catenin. Oncogene. 1999;18:2039–2046. [PubMed]
- Hatakeyama, S; Kitagawa, M; Nakayama, M; Shirane, M; Matsumoto, M; Hattori, K; Higashi, H; Nakano, H; Okumura, K; Onoe, K; Good, RA. Ubiquitin-dependent degradation of IκBα is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. Proc Natl Acad Sci USA. 1999;96:3859–3863. [PubMed]
- Spencer, E; Jiang, J; Chen, ZJ. Signal-induced ubiquitination of IκBα by the F-box protein Slimb/β-TrCP. Genes Dev. 1999;13:284–294. [PubMed]
- Suzuki, H; Chiba, T; Kobayashi, M; Takeuchi, M; Suzuki, T; Ichiyama, A; Ikenoue, T; Omata, M; Furuichi, K; Tanaka, K. IκBα ubiquitination is catalyzed by an SCF-like complex containing Skp1, cullin-1, and two F-box/WD40-repeat proteins, βTrCP1 and βTrCP2. Biochem Biophys Res Commun. 1999;256:127–132. [PubMed]
- Winston, JT; Strack, P; Beer-Romero, P; Chu, CY; Elledge, SJ; Harper, JW. The SCFβ-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IκBα ubiquitination in vitro. Genes Dev. 1999;13:270–283. [PubMed]
- Hart, M; Concordet, JP; Lassot, I; Albert, I; del los Santos, R; Durand, H; Perret, C; Rubinfeld, B; Margottin, F; Benarous, R; Polakis, P. The F-box protein β-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol. 1999;9:207–210. [PubMed]
- Kitagawa, M; Hatakeyama, S; Shirane, M; Matsumoto, M; Ishida, N; Hattori, K; Nakamichi, I; Kikuchi, A; Nakayama, K. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of β-catenin. EMBO J. 1999;18:2401–2410. [PubMed]
- Latres, E; Chiaur, DS; Pagano, M. The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of β-catenin. Oncogene. 1999;18:849–854. [PubMed]
- Lassot, I; Segeral, E; Berlioz-Torrent, C; Durand, H; Groussin, L; Hai, T; Benarous, R; Margottin-Goguet, F. ATF4 degradation relies on a phosphorylation-dependent interaction with the SCF(β-TrCP) ubiquitin ligase. Mol Cell Biol. 2001;21:2192–2202. [PubMed]
- Guardavaccaro, D; Kudo, Y; Boulaire, J; Barchi, M; Busino, L; Donzelli, M; Margottin-Goguet, F; Jackson, PK; Yamasaki, L; Pagano, M. Control of meiotic and mitotic progression by the F box protein β-Trcp1 in vivo. Dev Cell. 2003;4:799–812. [PubMed]
- Margottin-Goguet, F; Hsu, JY; Loktev, A; Hsieh, HM; Reimann, JD; Jackson, PK. Prophase destruction of Emi1 by the SCFβTrCP/Slimb ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. Dev Cell. 2003;4:813–826. [PubMed]
- Fong, A; Sun, SC. Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-κB2/p100. J Biol Chem. 2002;277:22111–22114. [PubMed]
- Lang, V; Janzen, J; Fischer, GZ; Soneji, Y; Beinke, S; Salmeron, A; Allen, H; Hay, RT; Ben Neriah, Y; Ley, SC. βTrCP-mediated proteolysis of NF-κB1 p105 requires phosphorylation of p105 serines 927 and 932. Mol Cell Biol. 2003;23:402–413. [PubMed]
- Mantovani, F; Banks, L. Regulation of the discs large tumor suppressor by a phosphorylation-dependent interaction with the β-TrCP ubiquitin ligase receptor. J Biol Chem. 2003;278:42477–42486. [PubMed]
- Kumar, KG; Tang, W; Ravindranath, AK; Clark, WA; Croze, E; Fuchs, SY. SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J. 2003;22:5480–5490. [PubMed]
- Busino, L; Donzelli, M; Chiesa, M; Guardavaccaro, D; Ganoth, D; Dorrello, NV; Hershko, A; Pagano, M; Draetta, GF. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature. 2003;426:87–91. [PubMed]
- Jin, J; Shirogane, T; Xu, L; Nalepa, G; Qin, J; Elledge, SJ; Harper, JW. SCFβ-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev. 2003;17:3062–3074. [PubMed]
- Watanabe, N; Arai, H; Nishihara, Y; Taniguchi, M; Watanabe, N; Hunter, T; Osada, H. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFβ-TrCP. Proc Natl Acad Sci USA. 2004;101:4419–4424. [PubMed]
- Li, Y; Suresh Kumar, KG; Tang, W; Spiegelman, VS; Fuchs, SY. Negative regulation of prolactin receptor stability and signaling mediated by SCFβ-TrCP E3 ubiquitin ligase. Mol Cell Biol. 2004;24:4038–4048. [PubMed]
- Zhou, BP; Deng, J; Xia, W; Xu, J; Li, YM; Gunduz, M; Hung, MC. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol. 2004;6:931–940. [PubMed]
- Wan, M; Tang, Y; Tytler, EM; Lu, C; Jin, B; Vickers, SM; Yang, L; Shi, X; Cao, X. Smad4 protein stability is regulated by ubiquitin ligase SCFβ-TrCP1. J Biol Chem. 2004;279:14484–14487. [PubMed]
- Sui, G; Soohoo, C; Affar, EB; Gay, F; Shi, Y; Forrester, WC; Shi, Y. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA. 2002;99:5515–5520. [PubMed]
- Hameed, M; Orrell, RW; Cobbold, M; Goldspink, G; Harridge, SD. Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. J Physiol. 2003;547:247–254. [PubMed]
- Carmichael, J; DeGraff, WG; Gazdar, AF; Minna, JD; Mitchell, JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987;47:936–942. [PubMed]
- Lee, DH; Goldberg, AL. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 1998;8:397–403. [PubMed]
- De Bosscher, K; Hill, CS; Nicolas, FJ. Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells. Biochem J. 2004;379:209–216. [PubMed]
- Zawel, L; Dai, JL; Buckhaults, P; Zhou, S; Kinzler, KW; Vogelstein, B; Kern, SE. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell. 1998;1:611–617. [PubMed]
- Feng, XH; Lin, X; Derynck, R. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-β. EMBO J. 2000;19:5178–5193. [PubMed]
- Voss, M; Wolff, B; Savitskaia, N; Ungefroren, H; Deppert, W; Schmiegel, W; Kalthoff, H; Naumann, M. TGFβ-induced growth inhibition involves cell cycle inhibitor p21 and pRb independent from p15 expression. Int J Oncol. 1999;14:93–101. [PubMed]
- Peng, B; Fleming, JB; Breslin, T; Grau, AM; Fojioka, S; Abbruzzese, JL; Evans, DB; Ayers, D; Wathen, K; Wu, T; Robertson, KD; Chiao, PJ. Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells. Clin Cancer Res. 2002;8:3628–3638. [PubMed]
- Imamura, T; Kanai, F; Kawakami, T; Amarsanaa, J; Ijichi, H; Hoshida, Y; Tanaka, Y; Ikenoue, T; Tateishi, K; Kawabe, T; Arakawa, Y; Miyagishi, M; Taira, K; Yokosuka, O; Omata, M. Proteomic analysis of the TGF-β signaling pathway in pancreatic carcinoma cells using stable RNA interference to silence Smad4 expression. Biochem Biophys Res Commun. 2004;318:289–296. [PubMed]
- Ijichi, H; Otsuka, M; Tateishi, K; Ikenoue, T; Kawakami, T; Kanai, F; Arakawa, Y; Seki, N; Shimizu, K; Miyazono, K; Kawabe, T; Omata, M. Smad4-independent regulation of p21/WAF1 by transforming growth factor-β. Oncogene. 2004;23:1043–1051. [PubMed]
- Iacobuzio-Donahue, CA; Song, J; Parmiagiani, G; Yeo, CJ; Hruban, RH; Kern, SE. Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res. 2004;10:1597–1604. [PubMed]
- Shi, Y; Hata, A; Lo, RS; Massague, J; Pavletich, NP. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature. 1997;388:87–93. [PubMed]
- Eppert, K; Scherer, SW; Ozcelik, H; Pirone, R; Hoodless, P; Kim, H; Tsui, LC; Bapat, B; Gallinger, S; Andrulis, IL; Thomsen, GH; Wrana, JL; Attisano, L. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 1996;86:543–552. [PubMed]
- de Caestecker, MP; Yahata, T; Wang, D; Parks, WT; Huang, S; Hill, CS; Shioda, T; Roberts, AB; Lechleider, RJ. The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain. J Biol Chem. 2000;275:2115–2122. [PubMed]
- Moren, A; Itoh, S; Moustakas, A; Dijke, P; Heldin, CH. Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4. Oncogene. 2000;19:4396–4404. [PubMed]
- Shi, X; Yang, X; Chen, D; Chang, Z; Cao, X. Smad1 interacts with homeobox DNA-binding proteins in bone morphogenetic protein signaling. J Biol Chem. 1999;274:13711–13717. [PubMed]
- Shi, X; Bai, S; Li, L; Cao, X. Hoxa-9 represses transforming growth factor-beta-induced osteopontin gene transcription. J Biol Chem. 2001;276:850–855. [PubMed]
- Wu, L; Wu, Y; Gathings, B; Wan, M; Li, X; Grizzle, W; Liu, Z; Lu, C; Mao, Z; Cao, X. Smad4 as a transcription corepressor for estrogen receptor alpha. J Biol Chem. 2003;278:15192–15200. [PubMed]
- Shimizu, K; Gurdon, JBA. A quantitative analysis of signal transduction from activin receptor to nucleus and its relevance to morphogen gradient interpretation. Proc Natl Acad Sci USA. 1996;96:6791–6796.
|